Nevro(NVRO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Nevro Reports Second-Quarter 2024 Financial Results Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, California – August 6, 2024 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life- ...